|
MUHC study reveals Vioxx related heart attacks can occur within the first two weeks of use
May 03, 2006A quarter of patients who suffered a heart attack while taking Vioxx did so within the first two weeks of taking the drug, a new study published by MUHC investigators reveals. The research, scheduled for early online publication in the Canadian Medical Association Journal (CMAJ) today, demonstrates that cardiovascular risks from taking Vioxx may occur much earlier than previously believed. "Our previous study on COX-2 inhibitors, which included Vioxx and Celebrex, evaluated whether there was an increased risk of heart attack while taking these medications; the answer was yes for Vioxx," says Linda Levesque, a doctoral student in the Department of Epidemiology and Biostatistics at McGill University, researcher at the MUHC in Montreal and lead author of the new study. "Our current study assessed the pattern of cardiovascular risk in Québec seniors over a three year period, in order to establish the timing of this risk."
Levesque, in collaboration with Dr. James Brophy , a cardiologist/epidemiologist and Director of the Technology Assessment Unit (TAU) at the MUHC and Associate Professor of Medicine at McGill University, and Bin Zhang, also a doctoral student in the Department of Epidemiology and Biostatistics, discovered that the risk of heart attack from Vioxx is much more acute than previously recognized. "A quarter of individuals in our study who suffered an acute myocardial infarction did so within two weeks of their first Vioxx prescription," says Levesque.
"The additional cardiovascular risk from Vioxx actually decreased with longer duration of use, suggesting that the period of highest susceptibility for most people taking Vioxx may occur earlier than previously believed," noted Levesque. The study also documents that cardiovascular risk returns to normal within one month of stopping the drug.
Vioxx was voluntarily withdrawn from the market on September 30, 2004 after a study showed it doubled patients' risk of heart attacks and strokes after 18 months of use. This MUHC study is the first to specifically address the question of the timing of cardiovascular risk associated with COX-2 inhibitors.
"This study adds important new information on how the COX-2 inhibitors like Vioxx affect the heart," said Dr. Peter Liu, Scientific Director of the CIHR Institute of Circulatory and Respiratory Health. "Physicians must carefully assess the risk versus benefit, and help the patient to watch for any new symptoms during the start of these medications. We are delighted that this research from the McGill University Health Centre can help us further to better the health of Canadians."
McGill University
Vioxx was voluntarily withdrawn from the market on September 30, 2004 after a study showed it doubled patients' risk of heart attacks and strokes after 18 months of use. This MUHC study is the first to specifically address the question of the timing of cardiovascular risk associated with COX-2 inhibitors.
"This study adds important new information on how the COX-2 inhibitors like Vioxx affect the heart," said Dr. Peter Liu, Scientific Director of the CIHR Institute of Circulatory and Respiratory Health. "Physicians must carefully assess the risk versus benefit, and help the patient to watch for any new symptoms during the start of these medications. We are delighted that this research from the McGill University Health Centre can help us further to better the health of Canadians."
McGill University
Vioxx News and Current Vioxx Events RSSToo much information? Study shows how ignorance can be influential
In the current issue of The RAND Journal of Economics, USC researchers provide a challenge to the classic economic model of information manipulation, in which knowing more than anybody else is the key to influence.
Popular Arthritis Drug May Disrupt Heart Rhythm, UB Research Finds
Celebrex, a popular arthritis drug that blocks pain by inhibiting an enzyme known as COX-2, has been shown in laboratory studies to induce arrhythmia, or irregular beating of the heart, via a novel pathway unrelated to its COX-2 inhibition.
FDA petition would protect public from dangerous drugs
In a petition filed today with the U.S. Food and Drug Administration, an international coalition of scientists and doctors seeks to compel the agency to stem the flood of dangerous drugs reaching American consumers by mandating the use of scientifically superior non-animal testing methods when those alternatives exist.
New study may explain Vioxx side effects
Vioxx and related pain medications were taken off the market in 2004 because they caused dangerous heart problems in some people.
K-State researcher examining why common anti-inflammatory drugs harm intestines
New versions of drugs like buffered aspirin and Vioxx could produce fewer harmful side effects thanks to research being done at Kansas State University's College of Veterinary Medicine.
Combining NSAIDs with chemotherapy, radiation may improve cancer treatment
Until recently, nonsteroidal anti-inflammatory drugs (NSAIDs) like aspirin and celecoxib (sold as Celebrex), were being hailed as promising cancer prevention drugs.
FDA causes unnecessary scare about common painkillers
The U.S. Food and Drug Administration (FDA) has caused an unnecessary scare about some pain relievers by adding a warning to drugs that are safe.
Blood pressure drug shows potential as lung cancer treatment
A hormone that is important in the control of blood pressure also shrinks lung cancer tumors in mice, suggesting a new way to prevent or treat the deadly cancer, according to scientists at Wake Forest University School of Medicine.
Study shows risk of acute pancreatitis low with statins
New research reveals that while cholesterol-lowering drugs do increase the risk of painful inflammation of the pancreas, the side effect is relatively rare, according to Sonal Singh, M.D., from Wake Forest University School of Medicine, and colleagues.
Researchers Uncover a Novel Mechanism of Action of a Potential New Drug for the Treatment of Multiple Sclerosis
Virginia Commonwealth University researchers have identified a unique mechanism of action of a new drug that shows great promise for the treatment of multiple sclerosis.
More Vioxx News Articles
| © 2008 BrightSurf.com |